Lupin is currently trading at Rs. 814.00, up by 1.10 points or 0.14% from its previous closing of Rs. 812.90 on the BSE.
The scrip opened at Rs. 810.00 and has touched a high and low of Rs. 815.40 and Rs. 810.00 respectively. So far 5675 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1498.40 on 23-Mar-2017 and a 52 week low of Rs. 782.10 on 07-Feb-2018.
Last one week high and low of the scrip stood at Rs. 835.85 and Rs. 808.00 respectively. The current market cap of the company is Rs. 36797.48 crore.
The promoters holding in the company stood at 47.02%, while Institutions and Non-Institutions held 37.64% and 15.35% respectively.
Lupin launches its Memantine Hydrochloride Extended-Release (ER) Capsules, 7mg, 14mg, 21mg, and 28mg having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Memantine Hydrochloride ER capsules are the generic equivalents of Allergan’s Namenda XR capsules. It is used for the treatment of moderate to severe dementia of the Alzheimer’s type. Memantine Hydrochloride had annual sales of approximately Rs 93.60 crore in the US for December 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
